CHARLOTTE, NC, December 3, 2021 – (BUSINESS WIRE) – cbdMD, Inc. (NYSE American: YCBD, YCBDpA) (the “Company”), one of the leading and most trusted and recognized cannabidiol (CBD). brands, announced today that it has begun a human preclinical study with researchers at the University of South Carolina. The study will explore the effects of cbdMD’s patented broad-spectrum cannabinoid blend on sleep, mood, and pain in healthy subjects to support the effectiveness of the company’s products. Studies will also measure key safety markers in healthy humans to increase the company’s safety dossiers for regulatory shipments. The company anticipates that these favorable results will be the basis for future research and drug applications by its therapeutic division.
“This partnership reaffirms to our consumers that cbdMD is committed to delivering products that have a real impact on their daily lives. We hope this study not only reaffirms that our products are safe and effective in supporting and maintaining a healthy lifestyle. , but also serve as a basis for future work to explore the clinical impact of our broad-spectrum cannabinoid mix in the areas that matter most to our clients.We want to educate our clients about the benefits of our products and this “This study is another example of our commitment to safety, quality and efficiency for our customers,” said Sibyl Swift, Ph.D., Vice President of Business. CbdMD Scientists and Regulators.
About cbdMD, Inc.
cbdMD, Inc. is one of the leading and most trusted and recognized cannabidiol (CBD) brands with a full line of THC1-free CBD products produced in the United States. Currently, the cbdMD brand includes more than 130 SKUs of high quality CBD products, including CBD tinctures, CBD jelly beans, CBD topicals, CBD capsules, CBD bath pumps, CBD bath salts, sleeping pills CBD, CBD beverage blends and full spectrum CBD options. Our Paw CBD pet product brand includes over 45 SKUs of veterinary formulated products that include tinctures, chews, topical products in different concentrations, and our CBD Botanicals skin care and beauty product brand includes 15 SKUs , which include facial oil and serum, toners and moisturizers. , fair skin, facial masks, scrubs and body care. The company also offers a full spectrum product line (approximately 10 SKUs) under its cbdMD brand. For more information on cbdMD and its full line of CBD-free CBD oil products in the United States, visit www.cbdmd.com, follow cbdMD on Instagram and Facebook, or visit one of the 6,000 outlets offering cbdMD products .
The story goes on
Prospective statements
This press release contains certain forward-looking statements that are based on current expectations and involve certain risks and uncertainties within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by using for words such as ” should ”, ” may, ” ” intend ”, ” anticipate ”, ” believe ”, ” estimate ”, ” projects, ” ” forecasts, ” ” wait ”, ” plan ” and ” propose ”. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. and could cause actual results to differ materially from those expressed or anticipated in the forward-looking statements, including, without limitation, statements made regarding the expansion of the consumer market for CBD products, our ability to increase our share market, the availability of the Amazon platform for our CBD products, our ability to expand our business and significantly increase our revenue, our ability to effectively leverage our brand partnerships and sponsorships, our ability to compete effectively in our market, our ability to achieve our net sales guidance and our ability to report profitable operations in the future. . We urge you to carefully review and consider any warnings and other disclosures, including statements made under the heading “Risk Factors” in the cbdMD, Inc. Annual Report. on Form 10-K for the fiscal year ended September 30, 2020 as filed with the Securities and Exchange Commission (the “SEC”) and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those of forward-looking statements, many of which are generally beyond the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. assumes no obligation to update any forward-looking statements unless required by law. The information on our websites and social media platforms, including Instagram and Facebook, is not part of this press release.
Without 1THC it is defined as below the level of detection by validated scientific methods.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20211203005299/ca/
Contacts
PR:
cbdMD, Inc.
Robert Pettway
Director of Public Relations
rpettway@cbdmd.com
(423) 503-5225
Investors:
cbdMD, Inc.
John Weston
Director of Investor Relations
john.weston@cbdmd.com
(704) 249-9515
